Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

HIFU Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1: Safety and Efficacy (cNF-HFU2101)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT05119582
Recruitment Status : Active, not recruiting
First Posted : November 15, 2021
Last Update Posted : June 24, 2022
Sahlgrenska University Hospital, Sweden
Information provided by (Responsible Party):
Joergen Serup, Bispebjerg Hospital

Brief Summary:

The overall objective is to demonstrate safety and efficacy of HIFU treatment of cutaneous neurofibromas located close to the surface of the skin in patients with the genetic disease Neurofibromatosis Type 1. The study will use a new investigational equipment that has been specially developed for dermatological therapy.

The study includes 20 patients in total distributed between the two centers, each having a minimum of 8 cutaneous neurofibromas eligible for treatment. All participants are adults (over 18 years) of both sexes.

The new treatment method is based on focusing intensive ultrasound just below the skin surface. This creates a very fast localized heating in small and very well-defined volumes containing neurofibroma tissue. This heating destroys or weakens the tissue, and the body's natural processes will subsequently transport affected cells away through the lymphatic and vascular systems. During the healing-process, the rejected tissue is replaced by new skin cells that are not expected to be fibrous.

The treatment is intended to be carried out without breaking the skin surface, and open wounds are therefore avoided. This is an essential advantage of the method compared to all existing therapies, which are based on physical removal of tumors through an open skin surface (e.g. surgery or laser therapy). Complications with risk of pain, infection and scarring will therefore be significantly reduced with the new proposed method.

The treatment is carried out by sending focused ultrasound from the handpiece of the equipment into the target area with neurofibromas. The equipment is set to send doses of approximately 150 milliseconds (0.15 seconds). The skin area and HIFU doses can be followed on the system computer screen and will be placed side-by-side with approximately 1-2 millimeter spacing. To achieve good energy transfer from handpiece to skin, ordinary ultrasound gel is used. There are no other special pre-treatments or preparations for the process. HIFU treatment is expected to be less painful than other treatments used. The treatment is quick, and typically takes less than 1 minute for a each area the size of a typical neurofibroma.

Condition or disease Intervention/treatment Phase
Cutaneous Neurofibroma Device: TOOsonix System ONE-M Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:

The study is a multicenter (two-center) open-label study with high-intensity focused ultrasound (HIFU) treatment of patients with the genetic disease Neurofibromatosis Type1.

The study is not comparative or randomized. The investigation is performed prior to CE mark to confirm safety and performance of the System ONE-M device when used as intended, i.e. as an non-invasive method to remove cutaneous neurofibromas by 20 MHz high intensity focused ultrasound.

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: High-Intensity Focused Ultrasound (HIFU), a Novel Method for Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1: Safety and Efficacy
Actual Study Start Date : April 13, 2022
Estimated Primary Completion Date : January 1, 2024
Estimated Study Completion Date : January 1, 2024

Arm Intervention/treatment
Experimental: TOOsonix System ONE-M
Cutaneous neurofibromas will be treated by high intensity focused ultrasound.
Device: TOOsonix System ONE-M
Selected neurofibromas will be treated by high intensity focused ultrasound. Untreated fibromas will be used for controls.

Primary Outcome Measures :
  1. Short Term Safety Profile - Adverse Events [ Time Frame: 3 months ]

    The grade of any adverse events (AE) requiring medical intervention within three months of treatment should be low. Device-based treatment will be considered tolerable if less than 30% of participants treated have an "Overall AE Score" larger than Grade 2 AE at the 3-month follow-up (visit 4).

    Measured by a grading scale based on Common Terminology Criteria for Adverse Events (CTCAE), U.S. Department of health and human services, Ver 5.0, Nov 27, 2017.

  2. Long Term Safety Profile - Healing [ Time Frame: 9 months ]

    The rate and nature of spontaneous healing of the treated cNF lesion and any safety related event including potential wound formation and wound healing should be equivalent to expectations from alternative method(s). Safety evaluation includes rating of treatment-associated sequele by end of study, e.g. dyspigmentation and scarring and overall investigator rating compared to expectations.

    Measured on 5-point grading from Very Unsatisfied to Very Satisfied.

Secondary Outcome Measures :
  1. Long Term Safety Profile - Adverse Events [ Time Frame: 9 months ]

    Any objective adverse effect or event, local or systemic, related to the treatment and the investigational device.

    Measured by a grading scale based on Common Terminology Criteria for Adverse Events (CTCAE), U.S. Department of health and human services, Ver 5.0, Nov 27, 2017.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and females 18 years of age or older.
  • Patients with a clinical diagnosis of NF1 based on germline genetic testing or by meeting the internationally recognized criteria given by the Clinical Care Advisory Board of the National Neurofibromatosis Foundation (now the Children's Tumor Foundation)
  • Patients must be seeking active treatment for cNF.
  • Patients must have ≥ 8 paired cNF that are visible and measure a minimum of 2 mm in size. These must be in areas amenable to treatment and surveillance.
  • Patients with Fitzpatrick Type I to VI skin-type
  • Able and willing to comply with all visits, treatments, evaluations, schedules, and requirements.
  • Patients shall have received oral and written study information, accepted participation and signed the informed consent document.
  • Patients who are willing and mentally and physically capable to understand and follow the treatment and follow-up schedule including post-treatment care instructions.
  • Patients who are willing to have photographs and images taken of the treated lesions to be used anonymously or coded in evaluations and publications.

Exclusion Criteria:

  • Patients who are undergoing other treatment modalities or investigational agents for their cNF lesions.
  • Individuals who cannot give informed consent or adhere to study schedule.
  • Patients who are actively tanning during the course of the study.
  • Patients with adverse reactions to compounds of any external agent in use.
  • Patients with known allergy to injectable anesthetics (relevant for biopsy only).
  • Patients with any condition which, in the Investigator's opinion, would make it unsafe (for the participant or study personnel) to treat the participant as part of this research study.
  • Patients, where target treatment may cause the acoustic beam to enter the eye.
  • Pregnant females, due to possible discomfort with the procedure even though the procedure is localized and there is no new drug.
  • Patients with tendency for keloid and hypertrophic scar formation .
  • Patients with impaired wound healing.
  • Patients with any other acute or chronic condition which, in the opinion of the investigator, could interfere with the conduct of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05119582

Layout table for location information
Bispebjerg Hospital
Copenhagen, Hovedstaden, Denmark, 2400
Sahlgrenska University Hospital
Gothenburg, Sweden, 41318
Sponsors and Collaborators
Joergen Serup
Sahlgrenska University Hospital, Sweden
Layout table for additonal information
Responsible Party: Joergen Serup, Professor, Chief Physician, Department of Dermatology, Bispebjerg Hospital Identifier: NCT05119582    
Other Study ID Numbers: CIV-21-09-037759
First Posted: November 15, 2021    Key Record Dates
Last Update Posted: June 24, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neurofibromatosis 1
Nerve Sheath Neoplasms
Neoplasms, Nerve Tissue
Neoplasms by Histologic Type
Neoplastic Syndromes, Hereditary
Neurocutaneous Syndromes
Nervous System Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Peripheral Nervous System Diseases
Neuromuscular Diseases
Peripheral Nervous System Neoplasms
Nervous System Neoplasms